Small Cell Lung Cancer Sclc clinical trials

Explore recruiting small cell lung cancer sclc clinical trials.

Recruiting small cell lung cancer sclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Small Cell Lung Cancer Sclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)

Hungary, France, Portugal, Greece, Sweden, Ireland +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Greece, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).

Belgium, Denmark, Italy, Austria, Greece, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

“Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer (the LUPER study).”

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in ≥2nd Line Small Cell Lung Cancer (SCLC) Treatment

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Small Cell Lung Cancer Sclc trials by city

Small Cell Lung Cancer Sclc in Toronto Small Cell Lung Cancer Sclc in Vancouver Small Cell Lung Cancer Sclc in Montreal Small Cell Lung Cancer Sclc in Calgary Small Cell Lung Cancer Sclc in Edmonton Small Cell Lung Cancer Sclc in Ottawa Small Cell Lung Cancer Sclc in Winnipeg Small Cell Lung Cancer Sclc in Quebec City Small Cell Lung Cancer Sclc in Hamilton Small Cell Lung Cancer Sclc in Kitchener Small Cell Lung Cancer Sclc in London Small Cell Lung Cancer Sclc in Halifax Small Cell Lung Cancer Sclc in New York Small Cell Lung Cancer Sclc in Los Angeles Small Cell Lung Cancer Sclc in Chicago Small Cell Lung Cancer Sclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease